Walnut Creek, CA, United States of America

Linda Masat

This inventor holds 20 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Antibody Therapeutics. Top assignees: Xoma Technology Ltd., Novartis Ag, Schering Corporation. Active years: 2009-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Linda Masat. Retrieved from https://idiyas.com/inventor/linda-masat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 2)

% Patents Active = 90.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 186(Granted Patents)

Location History:

Oakland, CA (US) (2009 - 2013)
Walnut Creek, CA (US) (2010 - 2017)

Company Filing History:

Xoma Techolology Ltd.

patent

where one patent can have more than one assignee

Years Active: 2009-2017

Loading Chart...

Areas of Expertise:

Antibodies

EphB3

IL-1β

Pharmaceuticals

Autoimmune Diseases

Coronary Conditions

VEGF

Gastrin

Human Antibodies

Inflammatory Diseases

Cancer Treatment

Therapeutics

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9541004 - Antagonist antibodies against EphB3 (2017-01-10),

2. 9206252 - Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof (2015-12-08),

3. 9006398 - EPHB3-specific antibody and uses thereof (2015-04-14),

4. 9005614 - PRLR-specific antibody and uses thereof (2015-04-14),

5. 8961969 - Antagonist antibodies against EphB3 (2015-02-24),

6. 8586716 - EPHB3-specific antibody and uses thereof (2013-11-19),

7. 8377442 - Method of treating inflammatory eye disease with IL-1β binding antibodies (2013-02-19),

8. 8377439 - Antagonist antibodies against EPHB3 (2013-02-19),

9. 8278421 - Human antibodies specific for gastrin materials and methods (2012-10-02),

10. 8216571 - Fully human anti-VEGF antibodies and methods of using (2012-07-10),

11. 7988968 - Method of treating an IL-1 related coronary condition (2011-08-02),

12. 7943121 - IL-1β binding antibodies and fragments thereof (2011-05-17),

13. 7867493 - PRLR-specific antibody and uses thereof (2011-01-11),

14. 7829094 - Method of treating an IL-1 related cancer (2010-11-09),

15. 7829093 - Method of treating an IL-1 related autoimmune disease or condition (2010-11-09),

Title: Innovations and Contributions of Linda Masat in the Field of Biopharmaceuticals

Introduction: Linda Masat, based in Walnut Creek, California, is an accomplished inventor with a strong portfolio of 20 patents. Her work primarily focuses on the development of innovative biopharmaceuticals, particularly in the realm of antibody technologies aimed at treating various diseases.

Latest Patents: Among her latest contributions, Linda has developed antagonistic antibodies against EphB3. These EphB3-specific antibodies not only represent a significant advancement in targeted therapies but also include pharmaceutical compositions and kits designed for the prevention and treatment of EphB3-related diseases or disorders. Additionally, she has patented pharmaceutical compositions comprising IL-1β binding antibodies and their fragments, which possess desirable affinity and potency. These innovations include essential nucleic acids, vectors, and methods for treating or preventing diseases, showcasing her commitment to advancing therapeutic strategies.

Career Highlights: Linda's career has been marked by her work with leading biopharmaceutical companies such as Xoma Technology Ltd. and Novartis AG. Her experiences at these organizations have helped shape her innovative approaches and have significantly contributed to her development of cutting-edge therapies in the biomedical field.

Collaborations: Throughout her career, Linda has collaborated with several esteemed colleagues, including Marina Roell and Mary Haak-Frendscho. These partnerships have undoubtedly enhanced her research and innovation endeavors, leading to the successful creation of multiple patented technologies.

Conclusion: Linda Masat continues to be a pivotal figure in the biopharmaceutical industry with her groundbreaking inventions and patents. Her contributions, particularly in the development of antibody-based therapies, not only reflect her expertise but also underline her commitment to improving healthcare through innovation.

Profile summary based on public USPTO records.